Susquehanna International Group’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $76K | Buy |
230,245
+147,161
| +177% | +$48.5K | ﹤0.01% | 5954 |
|
|
2025
Q1 | $25.9K | Buy |
83,084
+37,964
| +84% | +$11.8K | ﹤0.01% | 6119 |
|
|
2024
Q4 | $42.1K | Buy |
+45,120
| New | +$42.1K | ﹤0.01% | 5908 |
|
|
2024
Q1 | – | Sell |
-22,220
| Closed | -$71.5K | – | 6311 |
|
|
2023
Q4 | $71.5K | Buy |
+22,220
| New | +$71.5K | ﹤0.01% | 5453 |
|
|
2023
Q3 | – | Sell |
-16,958
| Closed | -$55.6K | – | 6125 |
|
|
2023
Q2 | $55.6K | Sell |
16,958
-146,808
| -90% | -$482K | ﹤0.01% | 5183 |
|
|
2023
Q1 | $423K | Buy |
163,766
+151,717
| +1,259% | +$391K | ﹤0.01% | 4042 |
|
|
2022
Q4 | $22.4K | Buy |
+12,049
| New | +$22.4K | ﹤0.01% | 5346 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 6684 |
|
|
2022
Q2 | – | Sell |
-307,874
| Closed | -$967K | – | 6428 |
|
|
2022
Q1 | $967K | Buy |
307,874
+21,504
| +8% | +$67.5K | ﹤0.01% | 2851 |
|
|
2021
Q4 | $919K | Buy |
286,370
+89,105
| +45% | +$286K | ﹤0.01% | 2974 |
|
|
2021
Q3 | $663K | Buy |
197,265
+90,545
| +85% | +$304K | ﹤0.01% | 3316 |
|
|
2021
Q2 | $417K | Sell |
106,720
-79,883
| -43% | -$312K | ﹤0.01% | 4101 |
|
|
2021
Q1 | $750K | Buy |
186,603
+23,444
| +14% | +$94.2K | ﹤0.01% | 3349 |
|
|
2020
Q4 | $377K | Buy |
163,159
+133,279
| +446% | +$308K | ﹤0.01% | 3685 |
|
|
2020
Q3 | $172K | Sell |
29,880
-40,403
| -57% | -$233K | ﹤0.01% | 3946 |
|
|
2020
Q2 | $518K | Sell |
70,283
-235,419
| -77% | -$1.74M | ﹤0.01% | 2889 |
|
|
2020
Q1 | $911K | Buy |
305,702
+189,367
| +163% | +$564K | ﹤0.01% | 2159 |
|
|
2019
Q4 | $483K | Buy |
+116,335
| New | +$483K | ﹤0.01% | 2692 |
|